1. Home
  2. BCRX vs MGNI Comparison

BCRX vs MGNI Comparison

Compare BCRX & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioCryst Pharmaceuticals Inc.

BCRX

BioCryst Pharmaceuticals Inc.

N/A

Current Price

$9.95

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Logo Magnite Inc.

MGNI

Magnite Inc.

N/A

Current Price

$24.37

Market Cap

2.7B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
BCRX
MGNI
Founded
1986
2007
Country
United States
United States
Employees
N/A
514
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.7B
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
BCRX
MGNI
Price
$9.95
$24.37
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
9
Target Price
$20.82
$25.22
AVG Volume (30 Days)
2.9M
2.9M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
381.40
493.75
EPS
N/A
0.16
Revenue
$25,186,000.00
$156,414,000.00
Revenue This Year
N/A
$6.28
Revenue Next Year
$12.55
$9.76
P/E Ratio
N/A
$153.70
Revenue Growth
N/A
25.45
52 Week Low
$6.00
$10.82
52 Week High
$11.22
$26.19

Technical Indicators

Market Signals
Indicator
BCRX
MGNI
Relative Strength Index (RSI) 55.95 62.20
Support Level $8.79 $11.26
Resistance Level $10.32 $25.41
Average True Range (ATR) 0.32 0.99
MACD 0.02 -0.12
Stochastic Oscillator 81.17 64.18

Price Performance

Historical Comparison
BCRX
MGNI

About BCRX BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

About MGNI Magnite Inc.

Magnite is a supply-side advertising platform that provides technology and yield management solutions to content publishers, enabling them to monetize their digital advertising inventory. Magnite receives a percentage of all advertising inventory that it sells. 43% of Magnite's revenue is derived from connected television, or CTV, streaming platforms, 40% from mobile applications, and the remainder from general websites. Beyond the typical monetization responsibilities inherent to an SSP, Magnite also provides upstream advertising servers to CTV publishers, allowing them to have granular control over direct-sold, programmatic guaranteed, and open-auction logic. Magnite competes with other independent SSPs, supply path optimization solutions, and closed ecosystems like Meta.

Share on Social Networks: